CDDD11-8
CDDD11-8 is an orally active, potent and selective inhibitor of CDK9 and FLT3-ITD, with Ki values of 8 and 13 nM, respectively. CDDD11-8 reduces the proliferation of leukemia cell lines and was particularly effective against those harboring FLT3-ITD mutation[1][2].
Product Specifications
CAS Number
2241659-94-7
UNSPSC
12352005
Target
CDK; FLT3
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cddd11-8.html
Purity
99.62
Solubility
10 mM in DMSO
Smiles
CC1=CN=C(N[C@@H]2CC[C@@H](N)CC2)N=C1C3=CN=C(C=C4)N3C=C4C5=CC=CC=C5
Molecular Formula
C24H26N6
Molecular Weight
398.50
References & Citations
[1]Anshabo AT, et al. An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia. Cancers (Basel) . 2022 Feb 22;14 (5) :1113.|[2]Mustafa EH, et al. Selective inhibition of CDK9 in triple negative breast cancer. Oncogene. 2023 Nov 24.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK9
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
IDLV022 1x 10^8 IFU/mL - 200 μL
SpCas9 (EF1a, Zeo) Integrase-Deficient Lentivirus
Sign In for Pricing
View Details